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The murine cytomegalovirus protein pp89, which is encoded by gene iel, is a nonstructural regulatory
protein expressed in the immediate-early phase of the viral replication cycle and located mainly in the nucleus
of infected cells. Protection of BALB/c (H-2d) mice against a lethal murine cytomegalovirus challenge infection
is achieved by vaccination with a recombinant vaccinia virus, MCMV-ieI-VAC, expressing pp89 as the only
murine cytomegalovirus gene product. The protection is entirely mediated by T lymphocytes of the CD8+
subset. In the present report, we analyzed the molecular basis of the recognition of pp89 by BALB/c CD8+
cytolytic T lymphocytes. A series of internal and terminal deletion mutants of gene ieI was constructed and
cloned in vaccinia virus, and the antigenicity and immunogenicity of the fragments of pp89 expressed by the
recombinants were studied. A region of only one-sixth of the protein, from amino acids 154 to 249 and encoded
by the fourth exon of gene iel, was sufficient for both the recognition in vitro of the protein by pp89-specific
cytotoxic T lymphocytes and the induction in vivo of pp89-specific cytotoxic T lymphocytes. By using synthetic
peptides, the sequence between residues 161 and 179, which is located within the defined domain, was identified
as an epitope presented to BALB/C cytotoxic T lymphocytes by the class I major histocompatibility antigen LU.
Cytomegalovirus (CMV) is an ubiquitous human pathogen
that is responsible for congenital malformations and causes
serious disease in patients immunocompromised during or-
gan transplantation or as a consequence of infection with
human immunodeficiency virus. Adequate and efficient
methods of prevention or treatment of CMV disease are
lacking (21, 23, 24). Recovery from CMV disease correlates
with a cellular immune response rather than with the pres-
ence of CMV-neutralizing antibodies (22, 25).
The infection of the mouse with murine CMV (MCMV)
serves as a model to study antiviral function and antigen
specificity of different lymphocyte subsets (10, 15, 17, 27-30,
41). By adoptive transfer experiments, it was shown that T
lymphocytes limit virus replication and prevent histopathol-
ogy (30). In particular, a protective effect against lethal
MCMV disease can be ascribed to CD8+ T lymphocytes
specific for immunodominant antigens expressed in the
immediate-early (IE) phase of the viral replication cycle (28,
29).
Within the 235-kilobase-pair MCMV DNA (7), gene
expression during the IE phase is limited to a region of 12
kilobase pairs, which includes the transcription units iel,
ie2, and ie3 (11, 12). Gene iel contained in transcription unit
iel encodes the major MCMV IE protein, the nonstructural
regulatory phosphoprotein pp89 (13). Virus-specific, major
histocompatibility complex class I-restricted cytolytic T
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lymphocytes (CTL) recognize pp89 (15, 17, 41). Vaccination
with a -recombinant vaccinia virus, MCMV-ieI-VAC, ex-
pressing pp89 as the only MCMV protein, induces protective
immunity (10, 41).
The reason why IE antigens represent immunodominant
antigens for CD8+ T lymphocytes (28) is unknown. Tran-
scription units iel and ie3 give rise to related transcripts and
proteins, due to the differential usage of at least five exons.
There is evidence for common usage of the transcription
start site and the first three exons, the first of which serves as
nontranslated leader (12, 13). Gene ieI, which encodes pp89,
comprises the first four exons (13). Recognition by CD8+ T
lymphocytes of amino acid sequences encoded by the sec-
ond and third exon could offer an explanation for the
immunodominance of IE antigens, because several IE pro-
teins in addition to pp89 share these sequences.
Domains and epitopes of a protein antigen recognized by
CD8+ T lymphocytes can be defined either by the expression
of protein fragments in target cells (37-39, 43) or by incuba-
tion of target cells with synthetic peptides derived from the
amino acid sequence of the protein (38, 40, 43). In this
communication, the combination of both methods allowed
us to conclude that a single domain of pp89 is relevant for
recognition by CD8+ T lymphocytes in BALB/c mice and
led to the identification of an epitope 19 amino acids in length
within this domain. The domain is entirely encoded by the
fourth exon of gene ieI and contains the sequences essential
for both immunogenicity and antigenicity of pp89.
MATERIALS AND METHODS
Mice. BALB/c mice (HI-2d haplotype) were bred in our
colony under specific-pathogen-free conditions.
Cells and viruses. The Smith strain of MCMV (VR-194;
American Type Culture Collection, Rockville, Md.) was
grown in third-passage BALB/c mouse embryo fibroblasts
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(MEF) and partially purified by sucrose gradient centrifuga-
tion. Wild-type and recombinant vaccinia viruses were
grown in Vero cells (African green monkey kidney fibro-
blasts), and homogenized cell extracts were used for priming
of mice and for the infection of the established cell lines
KD2SV (simian virus 40-transformed kidney fibroblasts
from B1O.D2 [H-2d] mice) (26) and L (fibroblasts from C3H
[H-2k] mice). L cells transfected with the gene for the MHC
class I molecule Ld (L/Ld cells) were described previously
(17). L cells transfected with Kd and Dd genes (L/Kd cells,
clone LSV 33-3 [5], and L/Dd cells, respectively) were
provided by M. Cochet and J. P. Abastado (Institute Pas-
teur, Paris). Surface expression of the Ld, Dd, and Kd
molecules in the transfected cell lines was confirmed by
cytofluorometric analysis with the monoclonal antibodies
B22-249 (19), 34.5.8S, and 31.3.4S (5) specific for Ld, Dd, and
Kd, respectively.
Construction of recombinant vaccinia viruses containing
deletion mutants of gene ieL. The continuous open reading
frame (ORF) of MCMV gene ieI, which was cloned as an
EcoRI fragment in the vaccinia virus expression vector
pGS62 (41), was transferred into plasmid pEMBL19(+) (6)
for mutagenesis and studies of gene expression in eucaryotic
cells. For this purpose, most of the iel ORF, including the
authentic ieI polyadenylation signal, was excised from
pGS62 as an HincII-EcoRI fragment and introduced into the
corresponding sites of pEMBL19(+). To provide the ieI
ORF with the 5' signals required for gene expression in
eucaryotic cells, the DraI-HincII fragment from plasmid
pIE111 encompassing the ieI promoter, the 5' mRNA leader
sequence, the first intron, the initiation codon, and coding
sequences upstream of the HincII site (16) was cloned into
the Hincll site of the ieIORF in pEMBL19(+). This plasmid
was designated p62/3. In the double-stranded form, p62/3
was used for the construction of the deletion mutants, as
described in Results. Single-stranded DNA isolated from
supernatants of phage Fl-infected Escherichia coli BMH71-
18 harboring p62/3 or the mutated plasmids was used for
confirming the accuracy of the deletions by sequencing.
Mutated ieI genes were isolated from p62/3 as EcoRI frag-
ments and, after cloning into plasmid pGS62, were inserted
into vaccinia virus as described previously (41).
Immunoprecipitation. L cells infected 12 h before with
recombinant vaccinia viruses at a multiplicity of infection of
20 PFU per cell were labeled for 2 h with 170 ,uCi of[35S]methionine per ml in methionine-free medium, and
immunoprecipitation of the cell lysates was performed as
described previously (14) with serum from mice latently
infected with MCMV and antiserum raised in rabbits against
the synthetic peptide P(34-53) of pp89 coupled to bovine
serum albumin (1, 4). The immunoprecipitated polypeptides
were analyzed by 10 to 20% acrylamide gradient gel electro-
phoresis.
Synthetic peptides. The peptides were synthesized by
using the Merrifield solid-phase techniques on an Applied
Biosystems peptide synthesizer and purified by high-pres-
sure liquid chromatography to more than 90% purity (32).
They were designated P(x-y), where x and y indicate the N-
and C-terminal amino acids, respectively, within the se-
quence of pp89.
Generation of cytolytic effector cells. The Ld-restricted
pp89-specific CTL clone IEl has been described previously
(17, 26, 31). For the production of polyclonal pp89-specific
CTL, mice were infected intravenously with 5 x 105 PFU of
recombinant vaccinia viruses. Three weeks later, spleen
cells were cultured at a concentration of 1.5 x 106 cells per
ml together with 1 x 105 PFU of MCMV and 1.5 x 105
stimulator cells per ml. Irradiated (30 Gy) spleen cells from
8-week-old mice which had been irradiated (6 Gy) and
lethally infected (2 x 105 PFU of MCMV, intraperitoneally)
8 to 12 days before served as stimulator cells. At day 5 of
culture, 25 U of recombinant human interleukin 2 (Sandoz
Forschungsinstitut, Vienna, Austria) was added per ml, and
the cultures were tested for cytolytic activity at day 7. For
the preparation of polyclonal MCMV-specific CTL, the
same procedure was followed, except that mice latently
infected with MCMV were used as the source of effector
cells. For the generation of polyclonal vaccinia virus-specific
CTL, mice were infected in one hind footpad with 2 x 107
PFU of wild-type vaccinia virus. At 6 days later, the
popliteal lymph node cells were taken and propagated in
vitro for 4 days in the presence of 100 U of recombinant
human interleukin 2 per ml.
Target cells and cytolytic assays. For selective expression
of IE genes, MEF were infected with MCMV at a multiplic-
ity of infection of 20 PFU per cell by centrifugation (800 x g,
30 min) in the presence of 50 ,ug of cycloheximide per ml,
which was replaced 3 h later by 5 ,ug of actinomycin D (28)
per ml. KD2SV cells and L cells were infected for 15 h with
wild-type or recombinant vaccinia viruses at a multiplicity of
20 PFU per cell. The target cells were then trypsinized and
labeled with Na251CrO4 for 90 min, and a standard 3-h
cytolytic assay was performed (28) with 1,000 target cells
and graded numbers of effector cells in twofold dilution
steps. Data represent the mean percentage of specific lysis
from three replicate cultures. For testing synthetic peptides,
the cells were pulsed with 100 ,uM peptide during the 90-min
51Cr labeling period, and excess peptide was removed by
washing of cells before incubation with effector cells (40).
Peptides that were scored negative by this method were
additionally tested after a second procedure, in which the
already 51Cr-labeled cells were dispensed into 96-well micro-
dilution plates containing the peptides at concentrations up
to 100 ,uM. After incubation for 30 min at 37°C, the cytolytic
effector cells were added, and the peptides were kept
throughout the assay (40).
RESULTS
Construction of the recombinant vaccinia viruses encoding
deletion mutants of pp89 gene iel. The major IE protein of
MCMV, pp89, is translated from the major IE mRNA, 2.75
kilobases in length, derived from transcription unit iel of the
MCMV genome (11-14). We have previously reported the
cloning into vaccinia virus of the continuous ieI ORF corre-
sponding to this major mRNA (41) (Fig. 1A). The pp89
expressed by the recombinant MCMV-ieI-VAC not only is
recognized in vitro by MCMV-specific CTL but can also
induce pp89-specific CTL in vivo that mediate protective
immunity against lethal MCMV challenge (10, 41). The
vaccinia virus vector system was now employed for mapping
the domains of pp89 that are essential for the antigenicity
and the immunogenicity of the protein for major histocom-
patibility complex class I-restricted CTL. Our strategy was
to study the effect that removal of defined regions of pp89
has on the cellular immune response.
A series of deletions spanning altogether 97% of the pp89
sequence were produced within gene ieI cloned in plasmid
p62/3, and the mutated genes were recombined into vaccinia
virus (Fig. 1B). The selected restriction enzymes served to
generate in-frame deletions. The DNA sequences flanking
the deletion sites were checked. Deletion mutant MCMV-
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FIG. 1. Structure of the deletion mutants of gene ieI encoding pp89. (A) The MCMV ieI gene, which is located between 0.78 and 0.80 map
units of the MCMV genome, has a length of 3,349 base pairs and comprises four exons, the first of which is noncoding (13). The continuous
ieI ORF, 1,785 base pairs in length (13), was derived from the ieI gene by site-directed mutagenesis (41). (B) Deletion mutants of the ieI ORF,
drawn to the same scale as the ieI ORF, were constructed and then cloned into vaccinia virus. Relevant restriction enzyme cleavage sites are
indicated as follows: Hc, HincII; E, EcoRV; B, BglII; P, PvuII; H, HindIll; X, XbaI; A, Asp718. The numbers below the constructs refer
to amino acid positions in pp89. For the mutated proteins, the residues of the authentic pp89 sequence flanking the deletions are indicated.
Hatched bars represent the pp89 sequence expressed, whereas open bars in AH and AJ indicate DNA sequences present in the recombinants
but not expressed due to a frame shift that created new stop codons. For each recombinant virus, the molecular mass (MM) of the encoded
protein was calculated from the amino acid sequence and is shown in comparison with the apparent molecular mass (MW) of the expression
products that were detected after immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
ieI-(AA)-VAC (abbreviated as AA) was constructed by
EcoRV digestion of p62/3. The ieI ORF contains one EcoRV
site, and a second EcoRV site is located in the intron that
separates the nontranslated leader sequence of the first exon
from the protein-coding sequences of the ORF (13). Cleav-
age resulted in the deletion of the single EcoRV fragment.
This isolated EcoRV fragment was digested with HincII, and
the shorter EcoRV-HincII fragment containing the transla-
tion start site was reintroduced into the p62/3 that lacked the
EcoRV fragment. AF was constructed as follows: plasmid
p62/3 contains three PvuII sites, only one of which is located
in the ieI ORF. A partial PvuII digestion linearized the
vector. Subsequent cleavage with EcoRV removed the
EcoRV fragment and the EcoRV-PvuII fragment upstream
of the PvuII site in the coding region. The isolated EcoRV
fragment was then reintroduced at its original position.
Although the deletions in AA and AF were sealed by blunt
end ligation of fragments, the preparation of the deletion
mutants AC, AH, and AJ required the creation of blunt ends
by using the Klenow fragment of DNA polymerase I before
ligation. To generate mutant AC, cleavage with HindIII and
Asp-718 removed all MCMV sequences between the HindIII
site in the multiple cloning site of plasmid pEMBL19(+) and
the Asp-718 site in the ieI ORF. The isolated HindIII
fragment was reintegrated, resulting in the loss of sequences
between the HindIII and Asp-718 sites in the ieI ORF.
Deletion mutants AJ and AH were also originally intended to
express the carboxy terminus of the protein (Fig. 1B).
During the deletion procedure, however, 1 and 2 base pairs,
respectively, were lost, thereby causing frameshifts that
resulted in the addition of 1 and 16 amino acids, respectively,
preceding translation termination codons. AH was con-
structed by removal of the HincII-XbaI fragment and sub-
sequent reintroduction of the smaller HincII-PvuII subfrag-
ment, and AJ was constructed by removal of the
HincII-HindIll fragment followed by reintroduction of the
HincII-BglII subfragment.
The expression of the pp89 deletion mutants in cells
infected with the recombinant vaccinia viruses was con-
firmed by immunoprecipitation (Fig. 2). In all cases, the
apparent molecular weight of the pp89 fragments was higher
than the calculated molecular mass (Fig. 1 and 2). This was
not unexpected, because the authentic pp89 is known to
migrate by a factor of 1.3 slower than expected from size
calculation (13). If the shift to higher molecular weight of
pp89 is due to contributions from certain regions of the
protein, we should expect to find different degrees of shift in
the different deletion mutants of pp89. Indeed, when the
calculated molecular masses were compared with the appar-
ent molecular weights, the factor of 1.3 did not apply to all
pp89 variants. In particular, the 35-kilodalton (kDa) frag-
ment of pp89 expressed by the recombinant AH (Fig. 2) had
migration properties in between the calculated molecular
mass (30 kDa) and the expected apparent molecular mass (40
kDa). This suggests that the C-terminal region of pp89
missing in AH is perhaps rich in posttranslational modifica-
tions. A minor difference in migration properties was also
observed in pp89 fragment expressed by the recombinant AF
(Fig. 1 and 2).
Mapping of the regions of pp89 essential for the antigenicity
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FIG. 2. Expression of deletion mutants of pp89 in cells infected
with recombinant vaccinia viruses. L cells were labeled for 2 h with
[35S]methionine 12 h after infection with the indicated recombinants,
and cell lysates, except that of recombinant AA, were immunopre-
cipitated with rabbit antiserum to peptide P(34-53). For the immu-
noprecipitation of the AA product, which lacks residues 34 through
53, MCMV immune serum was used. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis of the immunoprecipitates and of
a representative lysate containing the proteins specified by the
vaccinia virus vector (VAC) is shown. Apparent molecular masses
of the pp89 fragments are indicated in kilodaltons. Molecular weight
standards (M): 200, 92.5, 69, 46, 30, and 14.3 kDa.
of the protein for BALB/c CTL. The recognition by BALB/c
MCMV-specific CTL of the fragments of pp89 expressed by
the recombinant vaccinia viruses was analyzed by using
KD2SV cells, which express all H-2d class I molecules. Cells
infected with the recombinants AA, AC, and AH were
recognized by MCMV-specific polyclonal CTL to the same
extent as were those infected by MCMV-ieI-VAC encoding
the whole protein (Fig. 3). On the other hand, cells infected
with recombinants AF and AJ and control cells infected with
wild-type vaccinia virus were not lysed. The fact that AF
was not recognized, whereas AA and AH, which lack regions
of pp89 flanking the one that is missing in AF (Fig. 1), were
recognized, indicated that only the domain from amino acids
136 to 249 was essential for the antigenicity of pp89. More-
over, taking into account that AJ was also not recognized,
this domain could be further narrowed to pp89 amino acids
154 to 249.
The antigenic domain of pp89 is required for the immuno-
genicity of the protein in BALB/c mice. We studied next the
immunogenic properties of the fragments of pp89 expressed
by the recombinant viruses. It has been previously shown
that pp89 expressed by the recombinant MCMV-ieI-VAC is
able to prime pp89-specific CTL in BALB/c mice (41). We
now found that the pp89 fragments expressed by the recom-
binants AA, AC, and AH were as effective as the whole
protein in eliciting in vivo CTL that recognized pp89 ex-
pressed in MCMV-infected cells (Fig. 4). On the other hand,
the removal of the antigenic domain of the protein in AF and
AJ rendered these recombinants as ineffective in priming for
a pp89-specific CTL response as was wild-type vaccinia
virus.
These results demonstrated that the only domain of pp89
essential for priming and recognition by BALB/c CTL, in the
context of any H-2d class I molecule, was the one located
between amino acids 154 and 249. Removal of this antigenic
domain from the protein revealed that no immunogenic
domains exist outside of it.
Identification of amino acid sequences recognized by CTL
within the domain defined with the deletion mutants. The data
presented so far provided only negative evidence as to the
location within the protein of the epitopes recognized by
CTL. For positive evidence, in parallel to the analysis of the
deletion mutants, we screened the pp89 sequence for motifs
that could represent epitopes for T lymphocytes (33). The
peptides P(34-53), P(87-104), P(92-106), P(271-295), P(315-
328), and P(451-466) were synthesized and tested for their
ability to render uninfected cells that express H-2d class I
surface glycoproteins susceptible to lysis by pp89-specific
CTL. None of these peptides, all of which fortuitously lay
outside the domain between amino acids 154 and 249, was
recognized by the CTL (data not shown), thus supporting the
results obtained with the deletion mutants.
After completion of the deletion analysis, we focused the
search for putative epitope sequences on the defined do-
main, and the peptides P(161-179) and P(197-204) were
synthesized and tested. When pulsed with P(161-179),
KD2SV cells, which express all H-2d class I molecules, were
recognized and lysed by both a polyclonal MCMV-specific
CTL population and the pp89-specific, Ld-restricted CTL
clone IEl (Fig. 5). KD2SV cells pulsed with P(194-207) as
VAC
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FIG. 3. Recognition by BALB/c MCMV-specific CTL of deletion mutants of pp89 expressed in recombinant vaccinia virus-infected cells.
MCMV-specific CTL were generated by in vitro restimulation with MCMV of spleen cells derived from mice that were latently infected with
MCMV. KD2SV cells infected either with wild-type vaccinia virus (VAC) or with the indicated recombinants were used as target cells in the
cytolytic assay. The E:T ratio is the ratio of effector cells to target cells.
70-
.50
.Y
uE 30
10'
J. VIROL.
 at Universitaetsbibliothek M
uenchen on O
ctober 22, 2008 
jvi.asm.org
D
ow
nloaded from
 
ANTIGENIC DOMAIN FOR CTL IN MCMV IE PROTEIN pp89
VAC MCMV-iel-VAC
200 3 50 3
J0J~i
50 3 200 3
E:T ratio
200 3
&H
200 3 200 3
FIG. 4. Priming of pp89-specific CTL by deletion mutants of pp89 expressed by recombinant vaccinia viruses. Spleen cells were obtained
from BALB/c mice 3 weeks after intravenous infection with 5 x 107 PFU of either wild-type vaccinia virus (VAC) or the indicated
recombinants. After a secondary restimulation in vitro with MCMV, the specific cytolytic activity of the generated CTL was assayed on MEF
infected with MCMV under conditions of selective and enhanced expression of IE genes (0) or, as a control, on uninfected MEF (0).
well as KD2SV cells incubated without peptides were not
lysed. L cells (H-2k), which lack H-2d molecules, were not
able to present any of the peptides. We therefore concluded
that the region from amino acids 161 to 179 in pp89 consti-
tutes an epitope recognized by H-2d class I-restricted CTL.
Since recognition of pp89 by the CTL clone IEl is
restricted to the Ld glycoprotein (17, 26), we expected
P(161-179) to be presented in association with the Ld mole-
cule. We could not exclude, however, the possibility that it
might also be presented by other H-2d class I glycoproteins,
since for several epitopes recognized in association with
MHC class II glycoproteins presentation by more than one
restriction element has been described (18, 35). The conver-
sion to targets with the peptide P(161-179) of L cells trans-
fected with the gene encoding the MHC class I molecule Ld,
but not of those transfected with Dd or Kd, confirmed the
selective Ld-restricted recognition of this epitope by both
P (161-179 )
40
20
P (194-207)
40
20
50 3
20 1
50 3
20 1
E: T RATIO
FIG. 5. Recognition by BALB/c MCMV-specific CTL of a syn-
thetic peptide derived from the amino acid sequence of pp89.
Synthetic peptides P(161-179) and P(194-207), corresponding to
pp89 residues 161 to 179 and 194 to 207, respectively, were used at
a concentration of 100 ,uM to pulse uninfected KD2SV cells (H-2d)
(0, A) or L cells (H-2k) (0, A) during the labeling with 51Cr. As
effectors in the cytolytic assay, either MCMV-specific polyclonal
CTL (0, 0; E:T ratios ranging from 50:1 to 3:1) or the CTL clone
IEl (A, A; E:T ratios ranging from 20:1 to 1:1) were used.
polyclonal and clonal CTL (Fig. 6A). Surface expression of
the Ld, Dd, and Kd molecules was confirmed for each of the
transfected cell lines by cytofluorometric analysis with the
respective monoclonal antibodies specific for Ld, Dd, and Kd
(data not shown). In addition, all three MHC class I gene
transfectants, but not the untransfected L cells (data not
shown), were able to present vaccinia virus antigens to
BALB/c vaccinia-specific H-2d-restricted polyclonal CTL
(Fig. 6B), thus providing evidence for the functional integrity
of the transfected gene products.
In conclusion, the region from amino acids 154 to 249 of
pp89 represents the antigenic and immunogenic domain of
the protein for BALB/c MHC class I-restricted CTL and
contains an epitope that is recognized after presentation by
the Ld molecule (Fig. 7).
DISCUSSION
Vaccination of mice with a recombinant vaccinia virus,
MCMV-ieI-VAC, encoding the IE protein pp89 as the only
MCMV gene product (41), can protect against a lethal
challenge infection with MCMV. Protection is mediated by
pp89-specific CD8+ T lymphocytes (10). These results led us
to study which regions of the IE protein pp89 are immuno-
genic and antigenic for the virus-specific and MHC class
I-restricted CTL response in BALB/c (H-2d) mice. The
results show that the pp89-specific CTL response is entirely
directed to a domain comprising only one-sixth of the whole
protein, located between pp89 residues 154 and 249. An
epitope 19 amino acids in length was identified within this
region. When presented by the MHC class I glycoprotein Ld,
this epitope was recognized by both polyclonal MCMV-
specific CTL and the pp89-specific CTL clone IEL.
According to current concepts of antigen processing and
presentation for T lymphocytes, most protein antigens un-
dergo intracellular fragmentation yielding short peptides (36,
40). After binding to a single site on surface MHC molecules
(2, 9), such peptides are recognized by the antigen-specific
T-cell receptor (34). Recognition of protein antigens by
specific CTL has been demonstrated when target cells either
synthesized whole or fragmented proteins after transfection
(15, 17, 37-39, 43) or were incubated with synthetic peptides
derived from the amino acid sequence of the protein (38, 40,
43). By using these strategies, antigenic sequences of some
proteins could be defined. Although we have successfully
employed the transfection of cells to study the recognition of
pp89 by CTL (15, 17), the use of transfected cell lines is
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FIG. 6. Presentation of the pp89-derived synthetic peptide P(161-179) by the MHC class I glycoprotein Ld. A. The L/Ld, L/Dd, and L/Kd
cells were pulsed with P(161-179) or P(194-207) peptides, and their recognition by either MCMV-specific polyclonal CTL (0, 0; E:T ratios
ranging from 100:1 to 3:1) or by the CTL clone IEl (A, A; E:T ratios ranging from 20:1 to 0.6:1) was tested. B. Recognition by vaccinia
virus-specific polyclonal CTL of LILd, LIDd, and LIKd cells that were either not infected (LI) or infected with wild-type vaccinia virus (d).
limited. On the other hand, expression of gene fragments in
vaccinia virus offers the advantage that each construct can
be tested in vitro and in vivo in a variety of MHC hap-
lotypes.
The approach to construct a series of C-terminal trunca-
tions of a protein and to express them in vaccinia virus
s595
15t
1 i
249
161GRLMYDMYPHFMPTNLGPS179
FIG. 7. Epitope for BALB/c CTL in MCMV IE protein pp89.
The open bars represent the regions of pp89 (595 amino acids) that
are not essential for the CTL response. Small boxes indicate the
positions of sequences tested with synthetic peptides. The amino
acid sequence of the epitope defined by synthetic peptide P(161-179)
(filled box) is given in the one-letter code, with the proposed motif
for T-lymphocyte recognition underlined.
recombinants has recently been successfully used to map an
epitope detected by CTL clones specific for the glycoprotein
of the lymphocytic choriomeningitis virus (43). We followed
a similar but slightly different strategy. We intended not only
to define regions of pp89 which are relevant but also to
dismiss the regions that do not contribute to the antigenicity
and immunogenicity of the protein. This could not be
achieved with C-terminal deletions, because this approach
can only define but does not exclude domains, unless the
protein is truncated to an N-terminal fragment which fails to
be recognized by CTL. We therefore turned to the construc-
tion of internal in-frame deletion mutants of pp89.
It was expected that, if several domains within pp89 with
antigenic and immunogenic properties did exist, all in-frame
deletion mutants should be detected by some CTL in a
polyclonal population. Unlike the simian virus 40 T antigen,
in which antigenic epitopes located in several regions of the
protein are recognized by CTL (37), only one domain ofpp89
was found to be important for CTL induction and antigen
recognition by CTL in BALB/c mice. This domain was
negatively defined by deletion mutant AF lacking amino
acids 136 through 249. Recognition by CTL of mutants AA
and AH lacking the residues 20 through 135 and 250 through
595, respectively, confirmed that all epitopes must be lo-
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ANTIGENIC DOMAIN FOR CTL IN MCMV IE PROTEIN pp89
cated within this domain. A role for the first 153 amino acids
was excluded with mutant AJ, and thus the relevant domain
could be confined to the residues 154 through 249. The
possibility is not excluded that epitopes located at or very
close to the deletion points in AF or AJ might exist and have
been disrupted by the deletions. For other proteins, regions
far away from the actual epitope may influence the intensity
of the T-cell response to the epitope (8). It has been
suggested that these distant regions might be involved in the
processing of the protein. If this is the case also in pp89, such
regions should also be contained within the defined domain,
since deletion of all other regions affected neither the anti-
genicity nor the immunogenicity of the protein.
The domain is encoded entirely by the fourth exon of gene
iel in transcription unit iel. mRNA selected by DNA se-
quences from the transcription unit ie3 and translated into
protein does not hybridize to the fourth exon (12, 13). Thus,
ie3 products cannot contribute to the pp89-specific CTL
response. Previous work has identified proteins of 67, 51,
and 31 kDa in size that contain sequences derived from the
first three exons of transcription unit iel (12, 13). In addition,
all of them share with pp89 the monoclonal antibody 6/20/1
binding site (12), which has recently been mapped to amino
acid sequences encoded by the 3' region of the fourth exon
(M. Messerle et al., manuscript in preparation). Considering
the reduced size of these iel products, it is likely that some,
if not all, of these smaller iel products do not contain the
CTL epitope of pp89, which is encoded by the 5' region of
the fourth exon. Our results thus disfavor the idea that
several related IE proteins carrying the same epitope ac-
count for the immunodominance of IE antigens.
For positive identification of epitopes within the antigenic
and immunogenic domain of pp89, we made use of an
algorithm proposed to predict epitopes recognized by T
lymphocytes (33). A statistical analysis of several epitopes
has revealed a common sequence pattern consisting of a
charged amino acid or glycine followed by two or three
hydrophobic amino acids and a charged or polar amino acid.
We screened the whole pp89 for such motifs, and six
selected sequences were synthesized. They all failed to
render uninfected H-2d target cells susceptible to lysis by
both MCMV-specific polyclonal CTL and the pp89-specific
CTL clone IEI. It was not until we had defined the antigenic
domain and selected two peptides within it that an epitope
recognized by specific polyclonal and clonal CTL was found.
The epitope comprises amino acids 161 to 179, contains a
proposed pattern at residues 170 to 174, and is the first
described to be presented by the major histocompatibility
complex class I molecule Ld. Since some degree of similarity
is observed for epitopes presented by the same restriction
molecule (33), we hope that the identification of this epitope
will help in the search for Ld-restricted epitopes in other
protein antigens.
An unusual feature of this peptide is the fact that it
contains three prolines, an amino acid seldom found in
a-helices and in epitopes recognized by T lymphocytes,
many of which are supposed to adopt an (x-helical confor-
mation (20, 33). By studying the recognition by the CTL
clone IE1 of shorter or substituted derivatives of this pep-
tide, we expect to find out the optimal length of the epitope
and which residues are important for binding to the class I
molecule and for interaction with the T-cell receptor.
The recognition of the epitope at residues 161 through 179
presented by the Ld molecule does not exclude the possibil-
ity that CTL from the BALB/c strain can recognize also
other epitopes in pp89. We predict, however, that, if addi-
tional epitopes do exist they should be located within or
directly adjacent to residues 154 through 249. Final proof for
or against the existence of other pp89 epitopes presented by
class I molecules of the H-2d haplotype can be achieved after
definition of critical residues in the epitope core sequence of
residues 161 through 179, introduction of point mutations in
gene iel by site-directed mutagenesis, and study of the
immunological properties of the mutated pp89.
A long-term aim of our studies on the immunobiology of
the murine CMV infection is to test the feasibility of active
and passive immunization against CMV disease. We have
previously shown that vaccination with a vaccinia virus
recombinant expressing pp89 (10) and cytotherapy with
IE-specific CD8+ T lymphocytes (29) are protective. The
observation that the major IE protein of human CMV is also
a major antigen for human CTL (3; L. K. Borysiewicz and
J. G. B. Sissons, personal communication) encourages ex-
trapolation of the results to the human CMV disease. Since
vaccination with live vaccinia virus recombinants is not
advisable in the immunosuppressed host, subunit vaccines
have to be developed. Recently it was shown that immuni-
zation with a peptide from a herpesvirus glycoprotein can
induce a protective CD8+ T lymphocyte response (42). The
peptide of the nonstructural MCMV IE protein can be tested
accordingly.
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